DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

168
SECTION I
GENERAL PRINCIPLES
Rosner GL, Panetta JC, Innocenti F, Ratain MJ. Pharmacogenetic
pathway analysis of irinotecan. Clin Pharmacol Ther, 2008,
84:393–402.
Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants
of response to warfarin during initial anticoagulation.
N Engl J Med, 2008, 358:999–1008.
SEARCH Collaborative Group, Link E, Parish S, et al.
SLCO1B1 Variants and Statin-Induced Myopathy—A
Genomewide Study. N Engl J Med, 2008, 359:789–799.
Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation
predicts function of variants of the human organic cation
transporter, OCT1. Proc Natl Acad Sci USA, 2003, 100:
5902–5907.
Sills GJ, Mohanraj R, Butler E, et al. Lack of association
between the C3435T polymorphism in the human multidrug
resistance (MDR1) gene and response to antiepileptic drug
treatment. Epilepsia, 2005, 46:643–647.
Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase
(tpmt) genotype and early treatment response to mercaptopurine
in childhood acute lymphoblastic leukemia.
JAMA, 2005, 293:1485–1489.
Stegmaier K, Ross KN, Colavito SA, et al. Gene expressionbased
high-throughput screening(GE-HTS) and application to
leukemia differentiation. Na.Genet, 2004, 36:257–263.
Stephens JC, Schneider JA, Tanguay DA., et al. Haplotype variation
and linkage disequilibrium in 313 human genes. Science,
2001, 293:489–493.
Stranger BE, Forrest MS, Dunning M, et al. Relative impact of
nucleotide and copy number variation on gene expression phenotypes.
Science, 2007, 315:848–853.
Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for
studying complex genetic traits: Practical considerations. Nat
Rev Genet, 2002, 3:391–397.
Tai HL, Krynetski EY, Schuetz EG, et al. W.E. Enhanced proteolysis
of thiopurine S-methyltransferase (TPMT) encoded by
mutant alleles in humans (TPMT∗3a, TPMT∗2): Mechanisms
for the genetic polymorphism of tpmt activity. Proc Natl Acad
Sci USA, 1997, 94:6444–6449.
Tan S, Hall IP, Dewar J, et al. Association between beta
2-adrenoceptor polymorphism and susceptibility to bronchodilator
desensitisation in moderately severe stable asthmatics.
Lancet, 1997, 350:995–999.
Taylor DR, Kennedy MA. Genetic variation of the beta(2)-
adrenoceptor: Its functional and clinical importance in
bronchial asthma. Am J Pharmacogenom, 2001, 1:165–174.
Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in
OATP-C: Identification of multiple allelic variants associated
with altered transport activity among European- and Africanamericans.
J Biol Chem, 2001, 276:35669–35675.
Townsend DM, Tew KD. The role of glutathione-S-transferase in
anti-cancer drug resistance. Oncogene, 2003, 22:7369–7375.
Turgut S, Yaren A, Kursunluoglu R, Turgut G. MDR1 C3435T
polymorphism in patients with breast cancer. Arch Med Res,
2007, 38:539–544.
Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of
methotrexate: Toxicity among marrow transplantation patients
varies with the methylenetetrahydrofolate reductase C677T
polymorphism. Blood, 2001, 98:231–234.
Urban TJ, Gallagher RC, Brown C, et al. Functional genetic
diversity in the high-affinity carnitine transporter OCTN2
(SLC22A5). Mol Pharmacol, 2006, 70:1602–1611.
Vesell ES. Genetic and environmental factors causing variation
in drug response. Mutat Res, 1991, 247:241–257.
Vesell ES. Advances in pharmacogenetics and pharmacogenomics.
J Clin Pharmacol, 2000, 40:930–938.
Vesell ES, Page JG. Genetic control of drug levels in man:
Antipyrine. Science, 1968, 161:72–73.
Villafranca E, Okruzhnov Y, Dominguez MA, et al.
Polymorphisms of the repeated sequences in the enhancer
region of the thymidylate synthase gene promoter may predict
downstaging after preoperative chemoradiation in rectal cancer.
J Clin Oncol, 2001, 19:1779–1786.
Watters JW, Kraja A, Meucci MA, et al. Genome-wide discovery
of loci influencing chemotherapy cytotoxicity. Proc Natl Acad
Sci USA, 2004, 101:11809–11814.
Weinshilboum R. Inheritance and drug response. N Engl J Med,
2003, 348:529–537.
Weinshilboum R, Wang, L. Pharmacogenomics: Bench to bedside.
Nat Rev Drug Discov, 2004, 3:739–748.
Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics:
Monogenic inheritance of erythrocyte thiopurine methyltransferase
activity. Am J Hum Genet, 1980, 32:651–662.
Wen MS, Lee M, Chen JJ, et al. Prospective study of warfarin
dosage requirements based on CYP2C9 and VKORC1 genotypes.
Clin Pharmacol Ther, 2008, 84:83–89.
Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic
differences in drug disposition and response. Annu Rev
Pharmacol Toxicol, 2001, 41:815–850.
Xu ZH, Freimuth RR, Eckloff B, et al. Human 3′-phosphoadenosine
5′-phosphosulfate synthetase 2 (PAPSS2) pharmacogenetics:
Gene resequencing, genetic polymorphisms and functional
characterization of variant allozymes. Pharmacogenetics, 2002,
12:11–21.
Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis
of thiopurine S-methyltransferase deficiency: Genetic basis
for azathioprine and mercaptopurine intolerance. Ann Intern
Med, 1997, 126:608–614.